CVRx to Present at the Canaccord Genuity 43rd Annual Growth Conference
27 Juillet 2023 - 2:30PM
CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical
device company focused on developing, manufacturing and
commercializing innovative neuromodulation solutions for patients
with cardiovascular diseases, today announced that the management
team will present at Canaccord Genuity 43rd Annual Growth
Conference on Thursday, August 10, 2023. The Company is scheduled
to present at the conference at 8:30 am Eastern Time.
A live audio webcast of the conference presentation will be
available online at the investor relations page of the Company’s
website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on the
developing, manufacturing and commercializing innovative
neuromodulation solutions for patients with cardiovascular
diseases. Barostim™ is the first medical technology approved by FDA
that uses neuromodulation to improve the symptoms of patients with
heart failure. Barostim is an implantable device that delivers
electrical pulses to baroreceptors located in the wall of the
carotid artery. The therapy is designed to restore balance to the
autonomic nervous system and thereby reduce the symptoms of heart
failure. Barostim received the FDA Breakthrough Device designation
and is FDA-approved for use in heart failure patients in the U.S.
It has also received the CE Mark for heart failure and resistant
hypertension in the European Economic Area. To learn more about
Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike VallieICR
Westwicke443-213-0501ir@cvrx.com
Media Contact:
Laura O’NeillFinn
Partners402-499-8203laura.oneill@finnpartners.com
CVRx (NASDAQ:CVRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
CVRx (NASDAQ:CVRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024